Published in Clin Pharmacol Ther on September 28, 1966
The effect of "selective" beta-adrenoceptor blocking drugs on the myocardial circulation. Br J Pharmacol (1970) 1.31
Beta-adrenergic blocking activity of Yersinia pestis murine toxin. Infect Immun (1977) 1.22
Comparative effects of acebutolol and practolol on the lipolytic response to isoprenaline. Br J Clin Pharmacol (1976) 0.97
Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA (2001) 13.65
Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials (1997) 5.67
Recruitment experience in clinical trials: literature summary and annotated bibliography. Control Clin Trials (1987) 3.39
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 2.96
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 2.84
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Activities, events and outcomes in ambulatory patient care. N Engl J Med (1969) 2.63
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation (2000) 2.07
Misuse of hypnosis. Br Med J (1978) 2.07
Testing the level of ant activity associated with quorum sensing: An empirical approach leading to the establishment and test of a null-model. J Theor Biol (2010) 2.06
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med (1981) 1.89
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Hypnosis in the psychotherapy of neurotic illness. Br J Med Psychol (1975) 1.61
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation (2001) 1.46
Factors influencing the development of hypercholesterolemia after cardiac transplantation. Am J Cardiol (1992) 1.39
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol (2000) 1.27
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Mutation and sex in a competitive world. Nature (2000) 1.20
Increased leucocyte oxidative metabolism in hyperlipoproteinaemia. Lancet (1982) 1.20
Hypogammaglobulinemia with nodular lymphoid hyperplasia of the small bowel. Arch Intern Med (1968) 1.16
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Singular solutions of the diffusion equation of population genetics. J Theor Biol (2007) 1.13
Effects of a vigorous walking program on body composition, and carbohydrate and lipid metabolism of obese young men. Am J Clin Nutr (1979) 1.13
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med (1994) 1.10
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Cholesterol-lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia. Am J Clin Nutr (1990) 1.09
The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med (2001) 1.09
Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension. Am J Med (1986) 1.08
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology (1988) 1.04
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol (1998) 1.04
Near-periodic substitution and the genetic variance induced by environmental change. J Theor Biol (2005) 1.03
Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2001) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Relief of pain of Fabry's disease by diphenylhydantoin. Neurology (1973) 1.02
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol (1996) 1.00
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Fundamental insights into the random movement of animals from a single distance-related statistic. Am Nat (2009) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
Completely converting a blood service region to the use of safer plasma. Transfusion (2000) 0.97
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results. Control Clin Trials (1987) 0.94
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
Drug interactions. Pharmacol Physicians (1970) 0.93
The increase of the functional entropy of the human brain with age. Sci Rep (2013) 0.93
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med (1987) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes (1999) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Patient perceptions about the influence of cholesterol on heart disease. Am J Prev Med (1992) 0.91
Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc (1997) 0.91
Treatment of type III hyperlipoproteinemia with four different treatment regimens. Atherosclerosis (1984) 0.90
Blood lipids and lipoproteins in a Minnesota urban population. J Chronic Dis (1980) 0.90
Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. J Nutr (1997) 0.89
Sensitivity of the canine pancreatic intraductal pressure to subclinical reduction in cholinesterase acitivity. Ann Surg (1979) 0.89
Effect of cholestyramine and colestipol on the absorption of phenytoin. Eur J Clin Pharmacol (1983) 0.87
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake. J Am Diet Assoc (1994) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis (1991) 0.84
Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84
Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84
Physiological markers of smoking and their relation to coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial. Arteriosclerosis (1987) 0.84
Effects of selected hypolipidemic drugs on cell ultrastructure. Fed Proc (1971) 0.83